33 Results for "

Azido-mono-amide-DOTA

" in MedChemExpress (MCE) Product Catalog:
Products (33)

33 Results for "Azido-mono-amide-DOTA" in MCE Product Catalog:

Cat. No.: HY-W539916
CAS No.: 1227407-76-2
Azido-mono-amide-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Azido-mono-amide-DOTA can be used for conjugation of peptides and radionuclides.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P2336A
Target:  

Melanocortin Receptor

Research Areas:  

Cancer

CCZ01048 TFA, a α-MSH analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a Ki of 0.31 nM. CCZ01048 TFA shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 TFA is a promising candidate for PET imaging of malignant melanoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P1103
CAS No.: 1030384-98-5
Target:  

CXCR

Research Areas:  

Cancer

CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
loading...
    loading...
Cat. No.: HY-P4070
CAS No.: 1188379-43-2
Target:  

Insulin Receptor

Research Areas:  

Metabolic Disease

Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec modulates insulin receptor activity, controls blood glucose levels, reduces HbA1c levels, and binds reversibly to human serum albumin. Insulin icodec can be used for the research of type 2 diabetes mellitus .
loading...
    loading...
Cat. No.: HY-172320
CAS No.: 2919596-13-5
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

BMS-986238 is an orally active macrocyclic peptide PD-L1 inhibitor. BMS-986238 can be used in the research of tumors such as solid tumors and lymphomas .
loading...
    loading...
Cat. No.: HY-P11287A
DOTA-Pep-1L TFA is a polypeptide formed by the conjugation of DOTA and Pep-1L. DOTA-Pep-1L TFA specifically binds to IL13RA2 and can be used for the synthesis of targeted polypeptides. DOTA-Pep-1L TFA yields the isotopically labeled product [ 225Ac]DOTA-Pep-1L, which exerts α-radiation killing effects on orthotopic glioma cells and extends the median survival time of mice bearing orthotopic glioma models after stereotactic injection. DOTA-Pep-1L TFA can be used for PET imaging, tumor targeting and glioma research .
loading...
    loading...
Cat. No.: HY-P10131
CAS No.: 2803421-14-7
Research Areas:  

Cancer

3BP-3940 is a highly potent and selective peptide inhibitor of FAP that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. 3BP-3940 can be labeled with radionuclides (such as Ga-68) for precise tumor imaging or Lu-177 for the development of targeted anticancer technologies. 3BP-3940 accumulates in tumor lesions and can be used to diagnose and inhibit various solid cancers and CAFs-related diseases .
loading...
    loading...
Cat. No.: HY-P2112
CAS No.: 619300-53-7
Synonyms: DOTA-Nal3-octreotide
DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging . DOTA-NOC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
Cat. No.: HY-P10273A
DOTA-Octreotide TFA is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide TFA is used for research of cancer through combination with radioactive elements. DOTA-Octreotide TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
loading...
    loading...
Cat. No.: HY-P11287
DOTA-Pep-1L is a polypeptide formed by the conjugation of DOTA and Pep-1L. DOTA-Pep-1L specifically binds to IL13RA2 and can be used for the synthesis of targeted polypeptides. DOTA-Pep-1L yields the isotopically labeled product [ 225Ac]DOTA-Pep-1L, which exerts α-radiation killing effects on orthotopic glioma cells and extends the median survival time of mice bearing orthotopic glioma models after stereotactic injection. DOTA-Pep-1L can be used for PET imaging, tumor targeting and glioma research .
loading...
    loading...
Cat. No.: HY-158065
CAS No.: 1402795-92-9
Purity:  98.98%
Azido-mono-amide-DOTA-tris(t-Bu ester) is a biochemical assay reagent, and is a click chemistry reagent .
loading...
    loading...
Cat. No.: HY-P11026
Synonyms: DOTA-PEG4-TMVP1446
Target:  

VEGFR

Research Areas:  

Cancer

DOTA-TMVP1446 is a VEGFR-3 targeting peptide. DOTA-TMVP1446 labeled with 68Ga accurately detectes the status of lymph node metastasis, even in micrometastatic tumors, in the B16-F10 tumor mice model. DOTA-TMVP1446 can be used as a radiotracer for cancer-metastatic sentinel lymph nodes (m-SLN) imaging .
loading...
    loading...
Cat. No.: HY-P10444
CAS No.: 3033865-40-3
Research Areas:  

Cancer

DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
Cat. No.: HY-P5297
Research Areas:  

Cancer

DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
loading...
    loading...
Cat. No.: HY-P10307
Research Areas:  

Infection

DOTA-ubiquicidin (29-41), an antimicrobial peptide fragment derivative, can be used for synthesis of [ 68Ga]Ga-DOTA-Ubiquicidin29-41 and then used for imaging of infectious processes using PET/CT . DOTA-ubiquicidin (29–41) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
Cat. No.: HY-P5025
CAS No.: 1392269-21-4
Synonyms: Azido-c(RGDyK)
Target:  

Drug Intermediate

Research Areas:  

Others

Cyclo(Arg-Gly-Asp-D-Tyr-ε-azido-Nle) (Azido-c(RGDyK)) is a polypeptide composed of arginine, glycine, aspartic acid, and tyrosine that can be used for Synthesis of [ 18F]FPyKYNE-c(RGDyK) .
loading...
    loading...
Cat. No.: HY-P1103A
Target:  

CXCR

Research Areas:  

Cancer

CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
loading...
    loading...
Cat. No.: HY-P11293
CAS No.: 1309855-53-5
Target:  

Melanocortin Receptor

Research Areas:  

Cancer

DOTA-GGNle-CycMSHhex is a melanocortin-1 receptor (MC1R)-targeting peptide that can be radionuclide-labeled for melanoma imaging .
loading...
    loading...
Cat. No.: HY-P4757
CAS No.: 108081-77-2
Target:  

Parasite

Research Areas:  

Others

N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .
loading...
    loading...
Cat. No.: HY-P10951
CAS No.: 2647371-60-4
Synonyms: (R)-PSMA I&T; (R)-PNT-2002
Target:  

PSMA

Research Areas:  

Cancer

Zadavotide guraxetan (PSMA I&T; PNT-2002) is a prostate-specific membrane antigen (PSMA) inhibitor. Zadavotide guraxetan has antitumor activity and can be used in prostate cancer-targeted research .
loading...
    loading...